Back
Intellia Therapeutics, Inc. 10K Form
Sell
16
NTLA
Intellia Therapeutics, Inc.
Last Price:
$9.75
Seasonality Move:
-7.2%
7 Day Trial
ALL ACCESS PASS
$
7
Key Filings
10K form not available
Receive NTLA News And Ratings
See the #1 stock for the next 7 days that we like better than NTLA
NTLA Financial Statistics
Sales & Book Value
| Annual Sales: | $57.9M |
|---|---|
| Cash Flow: | $-76.9M |
| Price / Cash Flow: | 0 |
| Annual Sales: | $6.46 |
| Price / Book: | 1.4 |
Profitability
| EPS (TTM): | -4.26580 |
|---|---|
| Net Income (TTM): | $-445.8M |
| Gross Margin: | $47.6M |
| Return on Equity: | -54.66% |
| Return on Assets: | -43.08% |
Intellia Therapeutics, Inc. Earnings Forecast
Key Intellia Therapeutics, Inc. Financial Ratios
-
The Gross Profit Margin over the past 11 years for NTLA is 82.23%.
-
The Selling, General & Administrative Expenses for NTLA have been equal to 217.41% of Gross Profit Margin.
-
The Research & Development expenses have been 787.92% of Revenue.
-
The Net Earning history of NTLA is -896.77% of Total Revenues.
-
Per Share Earnings over the last 11 years have been positive in 3 years.
Intellia Therapeutics, Inc. Stock Price Chart
Industry, Sector and Symbol
| Stock Exchange: | NASDAQ |
|---|---|
| Industry: | Biotechnology |
| Sector: | Health Care |
| Current Symbol: | NTLA |
| CUSIP: | 45826J |
| Website: | intelliatx.com |
Debt
| Debt-to-Equity Ratio: | 0.13 |
|---|---|
| Current Ratio: | 6.21 |
| Quick Ratio: | 5.57 |
Price-to-Earnings
| Trailing P/E Ratio: | 0 |
|---|---|
| Forward P/E Ratio: | 0 |
NTLA Technical Analysis vs Fundamental Analysis
Sell
16
Intellia Therapeutics, Inc. (NTLA)
is a Sell
Is Intellia Therapeutics, Inc. a Buy or a Sell?
-
Intellia Therapeutics, Inc. stock is rated a SellThe current Intellia Therapeutics, Inc. [NTLA] share price is $9.06. The Score for NTLA is 16, which is 68% below its historic median score of 50, and infers higher risk than normal.